ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Dun & Bradstreet Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action

Rosen Law Firm reminded eligible Dun & Bradstreet shareholders of a November 10, 2026 deadline to seek lead-plaintiff status related to the company’s August 26, 2025 acquisition by Clearlake Capital affiliates. The transaction cashed out D&B shareholders at $9.15 per share; the notice applies to investors who sold shares between May 13 and August 26, 2025, exchanged shares in the merger, or held voting shares as of the May 9, 2025 record date.

Analysis

This is a plaintiff-law-firm solicitation, not evidence of a new legal development or a change in deal economics. With DNB already acquired for cash, there is no public-equity transmission mechanism and no basis to infer a valuation impact on Clearlake portfolio companies or listed information-services peers.

The practical issue is residual merger litigation: a lead-plaintiff deadline can eventually produce disclosure or fiduciary-duty claims, but such cases typically settle from D&O insurance or sponsor/company indemnities rather than alter operating strategy. Any financial exposure would be relevant only if a complaint identifies non-routine process defects, conflicts, or undisclosed bidder interactions; none is established by this notice.

No trade is warranted. For event-driven monitoring, the only potentially actionable catalyst over the next 1-6 months would be an actual filed complaint with detailed allegations, a ruling surviving dismissal, or evidence that the merger consideration was materially below a contemporaneous superior proposal. Absent those developments, treating the notice as a negative read-through for private-equity M&A is likely noise.

Key Decisions for Investors

• No position: do not establish litigation-driven exposure based on this solicitation; DNB is no longer a publicly traded vehicle.
• Set an alert for a substantive shareholder complaint or court ruling before/after the November 10, 2026 deadline; reassess only if allegations identify a credible competing-bid process failure or material undisclosed conflict.
• For broad private-equity or information-services exposures, maintain existing positions; do not use this item to short KKR, APO, BX, OWL, SPGI, MCO, or TRI. Thesis is falsified only by evidence of systemic financing, disclosure, or sponsor-governance implications beyond this transaction.